QPS Holdings, LLC has completed its acquisition of Xendo Drug Development BV (XDD). XDD, a European CRO headquartered in Groningen, The Netherlands, will be known as QPS Netherlands BV and is a wholly-owned subsidiary of QPS Holdings.

XDD has large and small molecule bioanalytical labs and a 24-bed clinical pharmacology unit (CPU) located at University Medical Center Groningen (UMCG). The CPU performs clinical pharmacology studies across all major therapeutic areas and provides comprehensive safety monitoring. XDD also has an extensive database of healthy volunteers as well as special and patient populations.

“Pooling our strengths will enable XDD and QPS to serve our clients even better. Our leading capability in conducting high quality bioanalysis and Phase I studies, combined with our well established expertise in ADME, genotyping and drug development process will make QPS an ideal drug development partner for our pharmaceutical and biotech clients worldwide,” said Ben Chien, chairman, and chief executive officer of QPS holdings.

“Joining the QPS organization enables XDD to realize its ambitions for global growth. In terms of activities, size and location, QPS and XDD are a perfect fit. Our combined operations in Asia, Europe and the U.S. position us ideally to expand our portfolios in the increasingly consolidated pharmaceutical and biotechnology sector, our primary market,” said Koos Koops, XDD’s former chief executive officer. Koops will head the XDD -QPS Netherlands division of QPS.